addit
season
influenza
viru
avian
influenza
virus
avian
influenza
also
infect
human
sinc
first
human
infect
novel
influenza
viru
confirm
china
spring
five
epidem
wave
human
infect
vaccin
effect
way
prevent
influenza
infect
howev
current
commerci
human
vaccin
avail
specif
antivir
treatment
anoth
critic
strategi
control
infect
neuraminidas
na
inhibitor
wide
use
drug
influenza
infect
howev
increas
drugresistanceconf
mutat
measur
also
need
treat
infect
previou
studi
shown
type
interferon
ifn
activ
influenza
pandem
highli
pathogen
strain
addit
natur
ifn
alferon
n
shown
inhibit
replic
oseltamivirsensit
resist
isol
primari
human
airway
epithelium
hae
cell
differenti
polar
hae
cell
subject
interfac
ali
cultur
week
morpholog
function
cell
resembl
vivo
human
pseudostratifi
mucociliari
epithelium
system
promis
tool
studi
respiratori
virus
mani
common
emerg
respiratori
virus
influenza
respiratori
syncyti
viru
rsv
adenoviru
adv
parainfluenza
viru
piv
human
coronaviru
hcov
replic
threedimension
hae
cell
moreov
newli
describ
virus
includ
hbov
hcov
could
cultur
tradit
cell
line
cultur
cell
current
avail
cell
cultur
model
hae
cell
reconstruct
morpholog
physiolog
characterist
respiratori
tract
greatest
extent
therefor
robust
cellular
model
respiratori
viru
research
also
use
evalu
therapeut
effect
drug
transgen
strategi
despit
type
type
iii
ifn
bind
differ
receptor
use
similar
signal
pathway
induc
express
overlap
set
ifnstimul
gene
isg
thu
type
iii
ifn
share
properti
type
ifn
role
antivir
defens
well
antiprolif
immunoregul
activ
studi
use
hae
cell
cultur
studi
target
cell
tropism
infect
prolifer
featur
antivir
activ
type
iii
type
recombin
human
ifn
rhifn
compar
cell
hae
cell
hae
cell
express
antivir
gene
differ
cell
model
also
analyz
obtain
chines
nation
influenza
center
experi
viru
perform
approv
enhanc
biosafeti
level
laboratori
cell
cultur
dulbecco
modifi
eagl
medium
dmem
gibco
ny
usa
fetal
bovin
serum
gibco
primari
hae
cell
isol
patient
underw
surgic
lung
resect
pulmonari
diseas
nanj
children
hospit
describ
previous
hae
cell
plate
onto
type
iii
collagenco
sixwel
tissu
cultur
plate
cultur
begm
media
lonza
germani
supplement
requir
addit
lonza
cell
reach
confluenc
tradit
monolay
twodimension
hae
cell
dissoci
trypsin
cell
seed
type
iv
collagenco
transwel
insert
costar
usa
medium
renew
apic
basolater
surfac
everi
day
medium
chang
interfac
ali
medium
begmdmemaddit
hae
cell
reach
full
confluenc
day
hae
cell
expos
air
basolater
compart
cultur
ali
medium
ali
cultur
continu
week
time
cell
differenti
pseudostratifi
hae
cell
prior
experi
cultur
maintain
incub
hae
cell
infect
tissu
cultur
infect
dose
h
fix
paraformaldehyd
pfa
min
room
temperatur
follow
wash
apic
basolater
side
three
time
pb
subsequ
fix
cell
permeabil
triton
x
h
block
bovin
serum
albumin
h
simultan
detect
protein
ciliat
cell
tight
junction
antiinfluenza
rabbit
polyclon
antibodi
thermo
fisher
mous
monoclon
tubulin
antibodi
sigma
mous
monoclon
antibodi
invitrogen
ca
usa
respect
appli
primari
antibodi
goatderiv
dylight
antimous
igg
h
l
thermo
fisher
dylight
antirabbit
igg
h
l
thermo
fisher
appli
secondari
antibodi
nuclei
counterstain
dapi
final
filter
cell
excis
insert
mount
coverslip
glass
slide
mount
medium
confoc
imag
taken
ultraview
vox
confoc
microscop
perkinelm
boston
usa
apic
surfac
hae
cell
rins
three
time
pb
incub
r
usa
iuml
yuanc
china
h
incub
discard
cell
cultur
supernat
hae
cell
inocul
apic
surfac
per
well
incub
h
viru
rhifn
diluent
prepar
ali
medium
end
incub
unbound
viral
particl
remov
rise
hank
buffer
basolater
compart
supplement
ml
ali
medium
h
incub
subsequ
ali
medium
ad
apic
surfac
supernat
collect
min
viru
rna
extract
use
qiaamp
minelut
viru
spin
kit
qiagen
hilden
germani
quantif
viral
yield
perform
use
onestep
rtpcr
reagent
abi
usa
analyz
effect
differ
rhifn
cell
experiment
method
similar
use
hae
cell
except
cell
cultur
plate
appli
viru
medium
dmem
ad
tpcktrypsin
nucleic
acid
extract
quantifi
per
day
day
realtim
pcr
assay
use
detect
ha
gene
primer
sequenc
probe
sequenc
famagataatgcattcccgcagattamra
hae
cell
rins
three
time
pb
incub
success
dilut
r
uml
yuanc
h
incub
next
cell
challeng
per
well
incub
h
unbound
viral
particl
remov
rise
hank
buffer
cell
supplement
begm
medium
harvest
collect
h
postinocul
rna
extract
nucleic
acid
quantif
perform
describ
analyz
effect
differ
rhifn
hae
cell
cell
experiment
protocol
describ
hae
cell
medium
use
cell
cultur
ali
medium
dmem
respect
apic
surfac
basolater
chamber
hae
cell
cultur
r
usa
iuml
yuanc
china
h
incub
ml
apic
surfac
basolater
chamber
respect
apic
surfac
wash
three
time
pb
follow
inocul
basolater
chamber
maintain
ml
ali
medium
incub
h
apic
chamber
wash
twice
pb
maintain
continu
ali
h
cell
fix
pfa
along
entir
transwel
insert
hematoxylineosin
stain
cell
hae
cell
welldifferenti
pseudostratifi
hae
cell
incub
iuml
yuanc
r
h
incub
rins
pb
cell
lyse
trizol
total
rna
extract
revers
transcript
perform
use
iii
firststrand
synthesi
system
invitrogen
rel
express
level
isg
includ
analyz
taqman
realtim
pcr
assay
use
method
gadph
use
intern
refer
sequenc
primer
probe
shown
tabl
import
compon
cytoskeleton
marker
protein
cilia
use
distinguish
ciliat
cell
noncili
cell
tight
junction
protein
zonula
locat
apex
epitheli
cell
major
compon
tight
junction
play
import
role
maintain
pseudostratifi
cell
layer
integr
barrier
function
shown
immunofluoresc
stain
iv
fig
fig
antibodi
could
infect
noncili
ciliat
cell
contrast
state
cilia
mock
control
hae
cell
infect
show
obviou
reduct
cilia
addit
hae
cell
show
disassoci
suggest
airway
epitheli
damag
cell
hae
cell
challeng
treat
iuml
ngml
h
viral
load
detect
realtim
pcr
consecut
day
use
method
describ
control
group
without
rhifn
treatment
viral
load
cell
reach
peak
copiesml
sixth
day
decreas
copiesml
tenth
day
fig
control
hae
cell
viral
load
reach
peak
copiesml
third
day
reduc
copiesml
tenth
day
fig
contrast
viral
load
cell
treat
rhifn
peak
second
day
gradual
decreas
fig
hae
cell
viral
replic
inhibit
first
day
rhifn
treatment
viral
load
reduc
copiesml
copiesml
third
day
later
gradual
rose
peak
copiesml
copiesml
sixth
day
gradual
decreas
fig
cell
hae
cell
hae
cell
incub
serial
dilut
rhifn
initi
concentr
iuml
respect
h
cell
challeng
viral
rna
extract
h
later
quantit
realtim
pcr
assay
target
ha
gene
conduct
quantifi
viral
load
among
three
cell
type
viral
prolifer
fastest
hae
cell
reach
copiesml
ha
gene
copi
number
cell
hae
cell
copiesml
copiesml
respect
antivir
activ
superior
three
cell
type
cell
fig
hae
cell
fig
hae
cell
fig
dose
rhifn
decreas
antivir
activ
also
decreas
demonstr
doserespons
relationship
compar
control
group
viral
load
decreas
copiesml
copiesml
mean
fold
copiesml
reduct
respect
hae
cell
treat
iuml
biggest
drop
viral
load
antivir
activ
rhifn
strongest
appli
cell
fig
stain
alicultur
hae
cell
reveal
nuclear
posit
uneven
appear
multilay
cell
cilia
distribut
top
morpholog
structur
similar
pseudostratifi
ciliat
columnar
epithelium
human
tracheal
tissu
infect
group
mani
vacuol
number
cilia
reduc
cell
layer
thinner
howev
hae
cell
incub
rhifn
challeng
cytopath
effect
infect
allevi
fig
rel
express
level
detect
realtim
pcr
use
gadph
intern
refer
compar
control
group
without
rhifn
treatment
cell
treat
either
significantli
upregul
express
level
four
gene
cell
hae
cell
express
level
four
gene
significantli
higher
group
group
contrast
isg
express
level
significantli
higher
group
group
hae
cell
fig
result
demonstr
gene
express
induc
rhifn
differ
hae
cell
ordinari
cell
human
popul
littl
immun
subtyp
influenza
never
previous
infect
human
thu
infect
may
high
mortal
rate
sinc
caus
five
outbreak
wave
laboratoryconfirm
case
infect
report
also
detect
anim
environ
therefor
pose
signific
threat
public
health
well
potenti
pandem
risk
current
univers
influenza
vaccin
avail
na
inhibitor
fdaapprov
drug
treatment
infect
rapid
emerg
na
inhibitorresist
strain
treatment
oseltamivir
util
na
inhibitor
clinic
treatment
influenzainfect
patient
limit
drug
requir
control
infect
tracheal
epitheli
cell
model
polar
differenti
establish
via
ali
cultur
subsequ
model
wide
use
amplif
isol
identif
respiratori
virus
well
studi
respiratori
viral
infect
therapeut
mechan
importantli
hae
system
greatli
facilit
isol
character
emerg
virus
unabl
prolifer
tradit
cell
notabl
antivir
effect
drug
observ
use
hae
may
reflect
actual
activ
drug
vivo
test
activ
type
type
iii
rhifn
differ
cultur
system
use
human
clinic
isol
advantag
immunostain
viru
cultur
cell
tropism
viru
detect
ciliat
cell
possess
sialic
acid
receptor
wherea
noncili
cell
present
mostli
sialic
acid
receptor
observ
infect
ciliat
cell
noncili
cell
viral
particl
bound
aviantyp
humantyp
confoc
imag
hae
cell
clearli
display
reduct
amount
cilia
destruct
tight
junction
compar
uninfect
control
approv
us
fda
clinic
treatment
diseas
hair
cell
leukemia
aidsrel
kaposi
sarcoma
chronic
hepat
b
c
achiev
great
social
econom
benefit
howev
longterm
use
may
caus
side
effect
fatigu
fever
anorexia
depress
associ
wide
distribut
receptor
contrast
type
iii
ifn
receptor
limit
distribut
mainli
epitheli
tissu
lung
intestin
side
effect
rel
minor
previou
studi
lab
shown
antivir
activ
higher
moreov
type
ifn
effect
influenza
pandem
highli
pathogen
strain
reason
chosen
studi
antivir
activ
influenza
viru
differ
cell
model
viral
yield
peak
day
postinfect
viru
cell
hae
cell
respect
viral
prolifer
profil
cell
also
differ
rhifn
treatment
addit
doseeffect
relationship
dose
activ
three
cell
type
antivir
activ
slightli
better
vari
degre
togeth
result
highlight
inconsist
replic
kinet
cell
hae
cell
well
differ
antivir
activ
rhifn
differ
cell
cell
adenocarcinom
human
alveolar
basal
epitheli
cell
hae
cell
use
studi
deriv
human
tracheal
tissu
tissu
sourc
two
cell
line
basic
two
chain
type
ifn
receptor
compon
type
iii
ifn
receptor
express
cell
anoth
compon
type
iii
ifn
receptor
express
certain
cell
report
express
cell
lung
tissu
almost
similar
use
northern
blot
analysi
express
level
type
type
iii
ifn
receptor
also
consist
bind
receptor
locat
cell
surfac
ifn
trigger
downstream
signal
pathway
eventu
induc
express
seri
isg
gene
target
multipl
stage
viral
life
cycl
exhibit
variou
antivir
activ
due
divers
structur
function
mainli
effect
viral
invas
act
primarili
viral
replic
transcript
stage
present
studi
express
level
cell
hae
cell
hae
cell
clearli
increas
incub
hae
cell
express
level
four
gene
significantli
higher
group
group
howev
noteworthi
correspond
result
exactli
opposit
hae
cell
indic
induct
isg
inconsist
cell
hae
cell
report
express
significantli
upregul
cell
treat
ngml
treatment
pgml
increas
express
level
studi
found
express
increas
markedli
follow
treatment
hae
cell
compar
result
hae
cell
addit
knockdown
express
result
remark
decreas
express
isg
cell
infect
influenza
viru
therebi
increas
viru
replic
although
upregul
ifninduc
observ
studi
rel
low
key
role
isg
ignor
remark
inhibit
replic
earli
viral
infect
addit
report
monomethyl
downregul
treatment
therebi
enhanc
activ
inhibit
influenza
viru
furthermor
overexpress
ifitm
protein
rigidifi
cell
membran
thu
markedli
inhibit
viral
membran
fusion
entri
play
import
role
pathogenesi
influenza
diseas
may
serv
potenti
target
treatment
manag
influenzaassoci
infect
recent
studi
ilyushina
colleagu
show
combin
na
inhibitor
oseltamivir
carboxyl
strong
synergist
interact
discoveri
suggest
rhifn
combin
na
inhibitor
might
effect
therapeut
strategi
infect
futur
work
investig
combin
therapi
appropri
cell
line
anim
model
cell
tropism
hae
cell
observ
bioactiv
differ
cell
cultur
system
test
result
indic
infect
ciliat
cell
noncili
cell
caus
cilia
tight
junction
damag
addit
replic
kinet
cell
hae
cell
differ
antivir
activ
cell
hae
cell
hae
cell
protect
effect
relat
induct
isg
